Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
A US Food and Drug Administration (FDA) advisory panel has voted in favor of the clinical benefit/risk profile of imetelstat for transfusion-dependent (TD) anemia in adults with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). 15 March 2024
More than 86% of the National Pharmaceutical Pricing Authority's (NPPA) total demand for overcharging remains unrecovered from drug majors operating in India. 15 March 2024
The US Food and Drug Administration (FDA) yesterday approved Rezdiffra (resmetirom) for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). 15 March 2024
New York-based neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA). 14 March 2024
German firms Bayer and Aignostics have announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. 14 March 2024
US clinical-stage pharma company Spruse Biosciences announced disappointing top-line results from its CAHmelia-203 study of tildacerfont. 14 March 2024
New real-world data show a positive safety profile for Xcopri (cenobamate), an anti-seizure medication which is offered in a tablet formulation. 14 March 2024
US RNA-targeted drug developer Ionis Pharmaceuticals has announced positive results from a Phase II study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). 14 March 2024
US biopharma company Catalyst Pharmaceuticals has announced the US commercial launch of Agamree (vamorolone) oral suspension for the treatment of Duchenne muscular dystrophy (DMD) in patients aged two years and older. 14 March 2024
Just a couple of months after launching its direct-to-consumer pharmacy service, Eli Lilly has announced plans to ramp things up significantly. 14 March 2024
US health technology assessor the Institute for Clinical and Economic Review (ICER) released a Final Evidence Report assessing the comparative clinical effectiveness and value of Novartis’ iptacopan and AstraZeneca subsidiary Alexion’s danicopan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). 14 March 2024
The US Food and Drug Administration (FDA) has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC). 14 March 2024
Swedish exports of pharmaceuticals reached a peak of 152.2 billion kronor (~$15 billion), which corresponds to 7.3% of the country’s total export value, and means an almost 10% p increase since 2022. 14 March 2024
Two privately-held American firms, Allumiqs and Prolytix, have announced a long-term, strategic partnership focused on: “optimizing drug development pipelines.” 13 March 2024
Pfizer has won European Commission (EC) approval for Prevenar 20 for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in children aged from six weeks to less than 18 years. 13 March 2024
Following discussions with the US regulator, Texan drugmaker Lexicon Pharmaceuticals now plans to resubmit a New Drug Application (NDA) for sotagliflozin. 12 March 2024